オピオイド受容体アゴニストのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Opioid Receptor Agonist Market Insights, Forecast to 2028

• レポートコード：QY2207E10435 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界のオピオイド受容体アゴニストの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にオピオイド受容体アゴニストの世界市場のxxx％を占める「フェンタニル」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のオピオイド受容体アゴニストの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのオピオイド受容体アゴニスト市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのオピオイド受容体アゴニスト市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 オピオイド受容体アゴニストのグローバル主要メーカーには、Teva Pharmaceutical Industries、Johnson & Johnson、Pfizer、Fresenius Kabi、Mylan N.V.、Allergan、US WorldMeds、Piramal Critical Care、DAIICHI SANKYO COMPANY、Purdue Pharma、Hikma Pharmaceuticals、Endo Pharmaceuticals、Sun Pharmaceutical Industries、Tris Pharma、Indiviorなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 オピオイド受容体アゴニスト市場は、種類と用途によって区分されます。世界のオピオイド受容体アゴニスト市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 フェンタニル、コデイン、モルヒネ、その他 【用途別セグメント】 病院薬局、オンライン薬局、小売薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - オピオイド受容体アゴニスト製品概要 - 種類別市場（フェンタニル、コデイン、モルヒネ、その他） - 用途別市場（病院薬局、オンライン薬局、小売薬局） - 調査の目的 ・エグゼクティブサマリー - 世界のオピオイド受容体アゴニスト販売量予測2017-2028 - 世界のオピオイド受容体アゴニスト売上予測2017-2028 - オピオイド受容体アゴニストの地域別販売量 - オピオイド受容体アゴニストの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別オピオイド受容体アゴニスト販売量 - 主要メーカー別オピオイド受容体アゴニスト売上 - 主要メーカー別オピオイド受容体アゴニスト価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（フェンタニル、コデイン、モルヒネ、その他） - オピオイド受容体アゴニストの種類別販売量 - オピオイド受容体アゴニストの種類別売上 - オピオイド受容体アゴニストの種類別価格 ・用途別市場規模（病院薬局、オンライン薬局、小売薬局） - オピオイド受容体アゴニストの用途別販売量 - オピオイド受容体アゴニストの用途別売上 - オピオイド受容体アゴニストの用途別価格 ・北米市場 - 北米のオピオイド受容体アゴニスト市場規模（種類別、用途別） - 主要国別のオピオイド受容体アゴニスト市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのオピオイド受容体アゴニスト市場規模（種類別、用途別） - 主要国別のオピオイド受容体アゴニスト市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のオピオイド受容体アゴニスト市場規模（種類別、用途別） - 主要国別のオピオイド受容体アゴニスト市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のオピオイド受容体アゴニスト市場規模（種類別、用途別） - 主要国別のオピオイド受容体アゴニスト市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのオピオイド受容体アゴニスト市場規模（種類別、用途別） - 主要国別のオピオイド受容体アゴニスト市場規模（トルコ、サウジアラビア） ・企業情報 Teva Pharmaceutical Industries、Johnson & Johnson、Pfizer、Fresenius Kabi、Mylan N.V.、Allergan、US WorldMeds、Piramal Critical Care、DAIICHI SANKYO COMPANY、Purdue Pharma、Hikma Pharmaceuticals、Endo Pharmaceuticals、Sun Pharmaceutical Industries、Tris Pharma、Indivior ・産業チェーン及び販売チャネル分析 - オピオイド受容体アゴニストの産業チェーン分析 - オピオイド受容体アゴニストの原材料 - オピオイド受容体アゴニストの生産プロセス - オピオイド受容体アゴニストの販売及びマーケティング - オピオイド受容体アゴニストの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - オピオイド受容体アゴニストの産業動向 - オピオイド受容体アゴニストのマーケットドライバー - オピオイド受容体アゴニストの課題 - オピオイド受容体アゴニストの阻害要因 ・主な調査結果

Opioids are a type of painkiller that works by acting on the neurological system. They’re mostly utilized for anaesthetic and pain relief. An agonist is a pharmacological molecule that activates specific brain receptors. When only a small number of receptors are engaged, this agonist elicits a strong physiological/pharmacological response, indicating that the medication has high intrinsic activity. Fentanyl, morphine, dihydromorphinone, meperidine, oxycodone, and oxymorphone are all strong agonist opioids. Opioid receptors are G-protein-coupled inhibitors that are primarily found in peripheral tissues and interfere with opioid receptors’ pain-signaling function. Agonists are pain relievers that function by binding opioid receptors and reducing pain experience.
Market Analysis and Insights: Global Opioid Receptor Agonist Market
Due to the COVID-19 pandemic, the global Opioid Receptor Agonist market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Fentanyl accounting for % of the Opioid Receptor Agonist global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
China Opioid Receptor Agonist market size is valued at US$ million in 2021, while the US and Europe Opioid Receptor Agonist are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Opioid Receptor Agonist landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Opioid Receptor Agonist include Teva Pharmaceutical Industries, Johnson & Johnson, Pfizer, Fresenius Kabi, Mylan N.V., Allergan, US WorldMeds, Piramal Critical Care and DAIICHI SANKYO COMPANY, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Opioid Receptor Agonist Scope and Segment
Opioid Receptor Agonist market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Opioid Receptor Agonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Fentanyl
Codeine
Morphine
Others
Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
By Company
Teva Pharmaceutical Industries
Johnson & Johnson
Pfizer
Fresenius Kabi
Mylan N.V.
Allergan
US WorldMeds
Piramal Critical Care
DAIICHI SANKYO COMPANY
Purdue Pharma
Hikma Pharmaceuticals
Endo Pharmaceuticals
Sun Pharmaceutical Industries
Tris Pharma
Indivior
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Opioid Receptor Agonist Product Introduction
1.2 Market by Type
1.2.1 Global Opioid Receptor Agonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Fentanyl
1.2.3 Codeine
1.2.4 Morphine
1.2.5 Others
1.3 Market by Application
1.3.1 Global Opioid Receptor Agonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Opioid Receptor Agonist Sales Estimates and Forecasts 2017-2028
2.2 Global Opioid Receptor Agonist Revenue Estimates and Forecasts 2017-2028
2.3 Global Opioid Receptor Agonist Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Opioid Receptor Agonist Sales by Region
2.4.1 Global Opioid Receptor Agonist Sales by Region (2017-2022)
2.4.2 Global Sales Opioid Receptor Agonist by Region (2023-2028)
2.5 Global Opioid Receptor Agonist Revenue by Region
2.5.1 Global Opioid Receptor Agonist Revenue by Region (2017-2022)
2.5.2 Global Opioid Receptor Agonist Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Opioid Receptor Agonist Sales by Manufacturers
3.1.1 Global Top Opioid Receptor Agonist Manufacturers by Sales (2017-2022)
3.1.2 Global Opioid Receptor Agonist Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Opioid Receptor Agonist in 2021
3.2 Global Opioid Receptor Agonist Revenue by Manufacturers
3.2.1 Global Opioid Receptor Agonist Revenue by Manufacturers (2017-2022)
3.2.2 Global Opioid Receptor Agonist Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Opioid Receptor Agonist Revenue in 2021
3.3 Global Opioid Receptor Agonist Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Opioid Receptor Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Opioid Receptor Agonist Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Opioid Receptor Agonist Sales by Type
4.1.1 Global Opioid Receptor Agonist Historical Sales by Type (2017-2022)
4.1.2 Global Opioid Receptor Agonist Forecasted Sales by Type (2023-2028)
4.1.3 Global Opioid Receptor Agonist Sales Market Share by Type (2017-2028)
4.2 Global Opioid Receptor Agonist Revenue by Type
4.2.1 Global Opioid Receptor Agonist Historical Revenue by Type (2017-2022)
4.2.2 Global Opioid Receptor Agonist Forecasted Revenue by Type (2023-2028)
4.2.3 Global Opioid Receptor Agonist Revenue Market Share by Type (2017-2028)
4.3 Global Opioid Receptor Agonist Price by Type
4.3.1 Global Opioid Receptor Agonist Price by Type (2017-2022)
4.3.2 Global Opioid Receptor Agonist Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Opioid Receptor Agonist Sales by Application
5.1.1 Global Opioid Receptor Agonist Historical Sales by Application (2017-2022)
5.1.2 Global Opioid Receptor Agonist Forecasted Sales by Application (2023-2028)
5.1.3 Global Opioid Receptor Agonist Sales Market Share by Application (2017-2028)
5.2 Global Opioid Receptor Agonist Revenue by Application
5.2.1 Global Opioid Receptor Agonist Historical Revenue by Application (2017-2022)
5.2.2 Global Opioid Receptor Agonist Forecasted Revenue by Application (2023-2028)
5.2.3 Global Opioid Receptor Agonist Revenue Market Share by Application (2017-2028)
5.3 Global Opioid Receptor Agonist Price by Application
5.3.1 Global Opioid Receptor Agonist Price by Application (2017-2022)
5.3.2 Global Opioid Receptor Agonist Price Forecast by Application (2023-2028)
6 North America
6.1 North America Opioid Receptor Agonist Market Size by Type
6.1.1 North America Opioid Receptor Agonist Sales by Type (2017-2028)
6.1.2 North America Opioid Receptor Agonist Revenue by Type (2017-2028)
6.2 North America Opioid Receptor Agonist Market Size by Application
6.2.1 North America Opioid Receptor Agonist Sales by Application (2017-2028)
6.2.2 North America Opioid Receptor Agonist Revenue by Application (2017-2028)
6.3 North America Opioid Receptor Agonist Market Size by Country
6.3.1 North America Opioid Receptor Agonist Sales by Country (2017-2028)
6.3.2 North America Opioid Receptor Agonist Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Opioid Receptor Agonist Market Size by Type
7.1.1 Europe Opioid Receptor Agonist Sales by Type (2017-2028)
7.1.2 Europe Opioid Receptor Agonist Revenue by Type (2017-2028)
7.2 Europe Opioid Receptor Agonist Market Size by Application
7.2.1 Europe Opioid Receptor Agonist Sales by Application (2017-2028)
7.2.2 Europe Opioid Receptor Agonist Revenue by Application (2017-2028)
7.3 Europe Opioid Receptor Agonist Market Size by Country
7.3.1 Europe Opioid Receptor Agonist Sales by Country (2017-2028)
7.3.2 Europe Opioid Receptor Agonist Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Opioid Receptor Agonist Market Size by Type
8.1.1 Asia Pacific Opioid Receptor Agonist Sales by Type (2017-2028)
8.1.2 Asia Pacific Opioid Receptor Agonist Revenue by Type (2017-2028)
8.2 Asia Pacific Opioid Receptor Agonist Market Size by Application
8.2.1 Asia Pacific Opioid Receptor Agonist Sales by Application (2017-2028)
8.2.2 Asia Pacific Opioid Receptor Agonist Revenue by Application (2017-2028)
8.3 Asia Pacific Opioid Receptor Agonist Market Size by Region
8.3.1 Asia Pacific Opioid Receptor Agonist Sales by Region (2017-2028)
8.3.2 Asia Pacific Opioid Receptor Agonist Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Opioid Receptor Agonist Market Size by Type
9.1.1 Latin America Opioid Receptor Agonist Sales by Type (2017-2028)
9.1.2 Latin America Opioid Receptor Agonist Revenue by Type (2017-2028)
9.2 Latin America Opioid Receptor Agonist Market Size by Application
9.2.1 Latin America Opioid Receptor Agonist Sales by Application (2017-2028)
9.2.2 Latin America Opioid Receptor Agonist Revenue by Application (2017-2028)
9.3 Latin America Opioid Receptor Agonist Market Size by Country
9.3.1 Latin America Opioid Receptor Agonist Sales by Country (2017-2028)
9.3.2 Latin America Opioid Receptor Agonist Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Opioid Receptor Agonist Market Size by Type
10.1.1 Middle East and Africa Opioid Receptor Agonist Sales by Type (2017-2028)
10.1.2 Middle East and Africa Opioid Receptor Agonist Revenue by Type (2017-2028)
10.2 Middle East and Africa Opioid Receptor Agonist Market Size by Application
10.2.1 Middle East and Africa Opioid Receptor Agonist Sales by Application (2017-2028)
10.2.2 Middle East and Africa Opioid Receptor Agonist Revenue by Application (2017-2028)
10.3 Middle East and Africa Opioid Receptor Agonist Market Size by Country
10.3.1 Middle East and Africa Opioid Receptor Agonist Sales by Country (2017-2028)
10.3.2 Middle East and Africa Opioid Receptor Agonist Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Teva Pharmaceutical Industries
11.1.1 Teva Pharmaceutical Industries Corporation Information
11.1.2 Teva Pharmaceutical Industries Overview
11.1.3 Teva Pharmaceutical Industries Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Teva Pharmaceutical Industries Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Teva Pharmaceutical Industries Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Corporation Information
11.2.2 Johnson & Johnson Overview
11.2.3 Johnson & Johnson Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Johnson & Johnson Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Johnson & Johnson Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Pfizer Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Fresenius Kabi
11.4.1 Fresenius Kabi Corporation Information
11.4.2 Fresenius Kabi Overview
11.4.3 Fresenius Kabi Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Fresenius Kabi Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Fresenius Kabi Recent Developments
11.5 Mylan N.V.
11.5.1 Mylan N.V. Corporation Information
11.5.2 Mylan N.V. Overview
11.5.3 Mylan N.V. Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Mylan N.V. Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Mylan N.V. Recent Developments
11.6 Allergan
11.6.1 Allergan Corporation Information
11.6.2 Allergan Overview
11.6.3 Allergan Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Allergan Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Allergan Recent Developments
11.7 US WorldMeds
11.7.1 US WorldMeds Corporation Information
11.7.2 US WorldMeds Overview
11.7.3 US WorldMeds Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 US WorldMeds Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 US WorldMeds Recent Developments
11.8 Piramal Critical Care
11.8.1 Piramal Critical Care Corporation Information
11.8.2 Piramal Critical Care Overview
11.8.3 Piramal Critical Care Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Piramal Critical Care Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Piramal Critical Care Recent Developments
11.9 DAIICHI SANKYO COMPANY
11.9.1 DAIICHI SANKYO COMPANY Corporation Information
11.9.2 DAIICHI SANKYO COMPANY Overview
11.9.3 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 DAIICHI SANKYO COMPANY Recent Developments
11.10 Purdue Pharma
11.10.1 Purdue Pharma Corporation Information
11.10.2 Purdue Pharma Overview
11.10.3 Purdue Pharma Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Purdue Pharma Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Purdue Pharma Recent Developments
11.11 Hikma Pharmaceuticals
11.11.1 Hikma Pharmaceuticals Corporation Information
11.11.2 Hikma Pharmaceuticals Overview
11.11.3 Hikma Pharmaceuticals Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Hikma Pharmaceuticals Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Hikma Pharmaceuticals Recent Developments
11.12 Endo Pharmaceuticals
11.12.1 Endo Pharmaceuticals Corporation Information
11.12.2 Endo Pharmaceuticals Overview
11.12.3 Endo Pharmaceuticals Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Endo Pharmaceuticals Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Endo Pharmaceuticals Recent Developments
11.13 Sun Pharmaceutical Industries
11.13.1 Sun Pharmaceutical Industries Corporation Information
11.13.2 Sun Pharmaceutical Industries Overview
11.13.3 Sun Pharmaceutical Industries Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Sun Pharmaceutical Industries Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Sun Pharmaceutical Industries Recent Developments
11.14 Tris Pharma
11.14.1 Tris Pharma Corporation Information
11.14.2 Tris Pharma Overview
11.14.3 Tris Pharma Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Tris Pharma Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Tris Pharma Recent Developments
11.15 Indivior
11.15.1 Indivior Corporation Information
11.15.2 Indivior Overview
11.15.3 Indivior Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Indivior Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Indivior Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Opioid Receptor Agonist Industry Chain Analysis
12.2 Opioid Receptor Agonist Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Opioid Receptor Agonist Production Mode & Process
12.4 Opioid Receptor Agonist Sales and Marketing
12.4.1 Opioid Receptor Agonist Sales Channels
12.4.2 Opioid Receptor Agonist Distributors
12.5 Opioid Receptor Agonist Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Opioid Receptor Agonist Industry Trends
13.2 Opioid Receptor Agonist Market Drivers
13.3 Opioid Receptor Agonist Market Challenges
13.4 Opioid Receptor Agonist Market Restraints
14 Key Findings in The Global Opioid Receptor Agonist Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Opioid Receptor Agonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Fentanyl
Table 3. Major Manufacturers of Codeine
Table 4. Major Manufacturers of Morphine
Table 5. Major Manufacturers of Others
Table 6. Global Opioid Receptor Agonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Opioid Receptor Agonist Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Opioid Receptor Agonist Sales by Region (2017-2022) & (K Units)
Table 9. Global Opioid Receptor Agonist Sales Market Share by Region (2017-2022)
Table 10. Global Opioid Receptor Agonist Sales by Region (2023-2028) & (K Units)
Table 11. Global Opioid Receptor Agonist Sales Market Share by Region (2023-2028)
Table 12. Global Opioid Receptor Agonist Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Opioid Receptor Agonist Revenue Market Share by Region (2017-2022)
Table 14. Global Opioid Receptor Agonist Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Opioid Receptor Agonist Revenue Market Share by Region (2023-2028)
Table 16. Global Opioid Receptor Agonist Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Opioid Receptor Agonist Sales Share by Manufacturers (2017-2022)
Table 18. Global Opioid Receptor Agonist Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Opioid Receptor Agonist Revenue Share by Manufacturers (2017-2022)
Table 20. Opioid Receptor Agonist Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Opioid Receptor Agonist Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Opioid Receptor Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid Receptor Agonist as of 2021)
Table 23. Opioid Receptor Agonist Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Opioid Receptor Agonist Product Offered
Table 25. Date of Manufacturers Enter into Opioid Receptor Agonist Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Opioid Receptor Agonist Sales by Type (2017-2022) & (K Units)
Table 28. Global Opioid Receptor Agonist Sales by Type (2023-2028) & (K Units)
Table 29. Global Opioid Receptor Agonist Sales Share by Type (2017-2022)
Table 30. Global Opioid Receptor Agonist Sales Share by Type (2023-2028)
Table 31. Global Opioid Receptor Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Opioid Receptor Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Opioid Receptor Agonist Revenue Share by Type (2017-2022)
Table 34. Global Opioid Receptor Agonist Revenue Share by Type (2023-2028)
Table 35. Opioid Receptor Agonist Price by Type (2017-2022) & (US$/Unit)
Table 36. Global Opioid Receptor Agonist Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global Opioid Receptor Agonist Sales by Application (2017-2022) & (K Units)
Table 38. Global Opioid Receptor Agonist Sales by Application (2023-2028) & (K Units)
Table 39. Global Opioid Receptor Agonist Sales Share by Application (2017-2022)
Table 40. Global Opioid Receptor Agonist Sales Share by Application (2023-2028)
Table 41. Global Opioid Receptor Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Opioid Receptor Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Opioid Receptor Agonist Revenue Share by Application (2017-2022)
Table 44. Global Opioid Receptor Agonist Revenue Share by Application (2023-2028)
Table 45. Opioid Receptor Agonist Price by Application (2017-2022) & (US$/Unit)
Table 46. Global Opioid Receptor Agonist Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America Opioid Receptor Agonist Sales by Type (2017-2022) & (K Units)
Table 48. North America Opioid Receptor Agonist Sales by Type (2023-2028) & (K Units)
Table 49. North America Opioid Receptor Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Opioid Receptor Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Opioid Receptor Agonist Sales by Application (2017-2022) & (K Units)
Table 52. North America Opioid Receptor Agonist Sales by Application (2023-2028) & (K Units)
Table 53. North America Opioid Receptor Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Opioid Receptor Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Opioid Receptor Agonist Sales by Country (2017-2022) & (K Units)
Table 56. North America Opioid Receptor Agonist Sales by Country (2023-2028) & (K Units)
Table 57. North America Opioid Receptor Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Opioid Receptor Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Opioid Receptor Agonist Sales by Type (2017-2022) & (K Units)
Table 60. Europe Opioid Receptor Agonist Sales by Type (2023-2028) & (K Units)
Table 61. Europe Opioid Receptor Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Opioid Receptor Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Opioid Receptor Agonist Sales by Application (2017-2022) & (K Units)
Table 64. Europe Opioid Receptor Agonist Sales by Application (2023-2028) & (K Units)
Table 65. Europe Opioid Receptor Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Opioid Receptor Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Opioid Receptor Agonist Sales by Country (2017-2022) & (K Units)
Table 68. Europe Opioid Receptor Agonist Sales by Country (2023-2028) & (K Units)
Table 69. Europe Opioid Receptor Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Opioid Receptor Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Opioid Receptor Agonist Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Opioid Receptor Agonist Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Opioid Receptor Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Opioid Receptor Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Opioid Receptor Agonist Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Opioid Receptor Agonist Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Opioid Receptor Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Opioid Receptor Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Opioid Receptor Agonist Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Opioid Receptor Agonist Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Opioid Receptor Agonist Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Opioid Receptor Agonist Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Opioid Receptor Agonist Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Opioid Receptor Agonist Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Opioid Receptor Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Opioid Receptor Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Opioid Receptor Agonist Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Opioid Receptor Agonist Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Opioid Receptor Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Opioid Receptor Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Opioid Receptor Agonist Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Opioid Receptor Agonist Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Opioid Receptor Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Opioid Receptor Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Opioid Receptor Agonist Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Opioid Receptor Agonist Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Opioid Receptor Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Opioid Receptor Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Opioid Receptor Agonist Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Opioid Receptor Agonist Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Opioid Receptor Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Opioid Receptor Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Opioid Receptor Agonist Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Opioid Receptor Agonist Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Opioid Receptor Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Opioid Receptor Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 107. Teva Pharmaceutical Industries Corporation Information
Table 108. Teva Pharmaceutical Industries Description and Major Businesses
Table 109. Teva Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Teva Pharmaceutical Industries Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Teva Pharmaceutical Industries Recent Developments
Table 112. Johnson & Johnson Corporation Information
Table 113. Johnson & Johnson Description and Major Businesses
Table 114. Johnson & Johnson Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Johnson & Johnson Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Johnson & Johnson Recent Developments
Table 117. Pfizer Corporation Information
Table 118. Pfizer Description and Major Businesses
Table 119. Pfizer Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. Pfizer Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Pfizer Recent Developments
Table 122. Fresenius Kabi Corporation Information
Table 123. Fresenius Kabi Description and Major Businesses
Table 124. Fresenius Kabi Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Fresenius Kabi Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Fresenius Kabi Recent Developments
Table 127. Mylan N.V. Corporation Information
Table 128. Mylan N.V. Description and Major Businesses
Table 129. Mylan N.V. Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. Mylan N.V. Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Mylan N.V. Recent Developments
Table 132. Allergan Corporation Information
Table 133. Allergan Description and Major Businesses
Table 134. Allergan Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Allergan Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Allergan Recent Developments
Table 137. US WorldMeds Corporation Information
Table 138. US WorldMeds Description and Major Businesses
Table 139. US WorldMeds Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 140. US WorldMeds Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. US WorldMeds Recent Developments
Table 142. Piramal Critical Care Corporation Information
Table 143. Piramal Critical Care Description and Major Businesses
Table 144. Piramal Critical Care Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 145. Piramal Critical Care Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Piramal Critical Care Recent Developments
Table 147. DAIICHI SANKYO COMPANY Corporation Information
Table 148. DAIICHI SANKYO COMPANY Description and Major Businesses
Table 149. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 150. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. DAIICHI SANKYO COMPANY Recent Developments
Table 152. Purdue Pharma Corporation Information
Table 153. Purdue Pharma Description and Major Businesses
Table 154. Purdue Pharma Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 155. Purdue Pharma Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Purdue Pharma Recent Developments
Table 157. Hikma Pharmaceuticals Corporation Information
Table 158. Hikma Pharmaceuticals Description and Major Businesses
Table 159. Hikma Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 160. Hikma Pharmaceuticals Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Hikma Pharmaceuticals Recent Developments
Table 162. Endo Pharmaceuticals Corporation Information
Table 163. Endo Pharmaceuticals Description and Major Businesses
Table 164. Endo Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 165. Endo Pharmaceuticals Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Endo Pharmaceuticals Recent Developments
Table 167. Sun Pharmaceutical Industries Corporation Information
Table 168. Sun Pharmaceutical Industries Description and Major Businesses
Table 169. Sun Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 170. Sun Pharmaceutical Industries Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Sun Pharmaceutical Industries Recent Developments
Table 172. Tris Pharma Corporation Information
Table 173. Tris Pharma Description and Major Businesses
Table 174. Tris Pharma Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 175. Tris Pharma Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Tris Pharma Recent Developments
Table 177. Indivior Corporation Information
Table 178. Indivior Description and Major Businesses
Table 179. Indivior Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 180. Indivior Opioid Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Indivior Recent Developments
Table 182. Key Raw Materials Lists
Table 183. Raw Materials Key Suppliers Lists
Table 184. Opioid Receptor Agonist Distributors List
Table 185. Opioid Receptor Agonist Customers List
Table 186. Opioid Receptor Agonist Market Trends
Table 187. Opioid Receptor Agonist Market Drivers
Table 188. Opioid Receptor Agonist Market Challenges
Table 189. Opioid Receptor Agonist Market Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid Receptor Agonist Product Picture
Figure 3. Global Opioid Receptor Agonist Market Share by Type in 2021 & 2028
Figure 3. Fentanyl Product Picture
Figure 4. Codeine Product Picture
Figure 5. Morphine Product Picture
Figure 6. Others Product Picture
Figure 7. Global Opioid Receptor Agonist Market Share by Application in 2021 & 2028
Figure 8. Hospital Pharmacy
Figure 9. Online Pharmacy
Figure 10. Retail Pharmacy
Figure 11. Opioid Receptor Agonist Report Years Considered
Figure 12. Global Opioid Receptor Agonist Sales 2017-2028 (K Units)
Figure 13. Global Opioid Receptor Agonist Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Opioid Receptor Agonist Revenue 2017-2028 (US$ Million)
Figure 15. Global Opioid Receptor Agonist Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Opioid Receptor Agonist Sales Market Share by Region (2017-2022)
Figure 17. Global Opioid Receptor Agonist Sales Market Share by Region (2023-2028)
Figure 18. North America Opioid Receptor Agonist Sales YoY (2017-2028) & (K Units)
Figure 19. North America Opioid Receptor Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Opioid Receptor Agonist Sales YoY (2017-2028) & (K Units)
Figure 21. Europe Opioid Receptor Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Opioid Receptor Agonist Sales YoY (2017-2028) & (K Units)
Figure 23. Asia-Pacific Opioid Receptor Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Opioid Receptor Agonist Sales YoY (2017-2028) & (K Units)
Figure 25. Latin America Opioid Receptor Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Opioid Receptor Agonist Sales YoY (2017-2028) & (K Units)
Figure 27. Middle East & Africa Opioid Receptor Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Opioid Receptor Agonist Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Opioid Receptor Agonist in the World: Market Share by Opioid Receptor Agonist Revenue in 2021
Figure 30. Global Opioid Receptor Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Opioid Receptor Agonist Sales Market Share by Type (2017-2028)
Figure 32. Global Opioid Receptor Agonist Revenue Market Share by Type (2017-2028)
Figure 33. Global Opioid Receptor Agonist Sales Market Share by Application (2017-2028)
Figure 34. Global Opioid Receptor Agonist Revenue Market Share by Application (2017-2028)
Figure 35. North America Opioid Receptor Agonist Sales Market Share by Type (2017-2028)
Figure 36. North America Opioid Receptor Agonist Revenue Market Share by Type (2017-2028)
Figure 37. North America Opioid Receptor Agonist Sales Market Share by Application (2017-2028)
Figure 38. North America Opioid Receptor Agonist Revenue Market Share by Application (2017-2028)
Figure 39. North America Opioid Receptor Agonist Sales Share by Country (2017-2028)
Figure 40. North America Opioid Receptor Agonist Revenue Share by Country (2017-2028)
Figure 41. United States Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Opioid Receptor Agonist Sales Market Share by Type (2017-2028)
Figure 44. Europe Opioid Receptor Agonist Revenue Market Share by Type (2017-2028)
Figure 45. Europe Opioid Receptor Agonist Sales Market Share by Application (2017-2028)
Figure 46. Europe Opioid Receptor Agonist Revenue Market Share by Application (2017-2028)
Figure 47. Europe Opioid Receptor Agonist Sales Share by Country (2017-2028)
Figure 48. Europe Opioid Receptor Agonist Revenue Share by Country (2017-2028)
Figure 49. Germany Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 50. France Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Opioid Receptor Agonist Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Opioid Receptor Agonist Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Opioid Receptor Agonist Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Opioid Receptor Agonist Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Opioid Receptor Agonist Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Opioid Receptor Agonist Revenue Share by Region (2017-2028)
Figure 60. China Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 63. India Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 65. China Taiwan Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 69. Latin America Opioid Receptor Agonist Sales Market Share by Type (2017-2028)
Figure 70. Latin America Opioid Receptor Agonist Revenue Market Share by Type (2017-2028)
Figure 71. Latin America Opioid Receptor Agonist Sales Market Share by Application (2017-2028)
Figure 72. Latin America Opioid Receptor Agonist Revenue Market Share by Application (2017-2028)
Figure 73. Latin America Opioid Receptor Agonist Sales Share by Country (2017-2028)
Figure 74. Latin America Opioid Receptor Agonist Revenue Share by Country (2017-2028)
Figure 75. Mexico Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 76. Brazil Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 77. Argentina Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Opioid Receptor Agonist Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Opioid Receptor Agonist Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Opioid Receptor Agonist Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Opioid Receptor Agonist Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Opioid Receptor Agonist Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Opioid Receptor Agonist Revenue Share by Country (2017-2028)
Figure 84. Turkey Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Opioid Receptor Agonist Revenue (2017-2028) & (US$ Million)
Figure 87. Opioid Receptor Agonist Value Chain
Figure 88. Opioid Receptor Agonist Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

---